Krystal Biotech develops and makes gene therapies, including VYJUVEK, a topical treatment for a rare inherited skin disease. KRYS reports earnings on Mon, Nov 2, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in KRYS, 50% of them bullish and 50% bearish. In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for KRYS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRYS is in one of them and how their past KRYS trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Krystal Biotech
Krystal Biotech is a biotechnology company based in Pittsburgh, Pennsylvania, that develops and manufactures gene therapies. Its platform uses an engineered herpes simplex virus to deliver therapeutic genes to target cells. Its approved product, VYJUVEK, is applied directly to the skin to treat dystrophic epidermolysis bullosa, a rare inherited skin disease, and is sold in the United States, Europe and Japan. The company also has clinical stage candidates for other rare diseases.
